Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition for the prevention or treatment of degenerative neurological brain disorders

一种神经退行性、组合物的技术，应用在药物组合、神经系统疾病、医药配方等方向，能够解决延迟认知功能退化、没有实现等问题，达到抑制活性氧和兴奋性脑神经递质、抑制细胞凋亡、增强记忆力的效果

Active Publication Date: 2013-05-01
SEOUL NAT UNIV R&DB FOUND
View PDF4 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, it is well known that its main purpose, delaying the decline of cognitive functions, was not achieved (Pillon et al., Cognitive deficits and dementia in Parkinson's disease. 2ed. Amsterdam; Elsevier Science; 2001)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Pharmaceutical composition for the prevention or treatment of degenerative neurological brain disorders
  • Pharmaceutical composition for the prevention or treatment of degenerative neurological brain disorders
  • Pharmaceutical composition for the prevention or treatment of degenerative neurological brain disorders

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0062] Embodiment 1: the synthesis of methyl p-hydroxybenzoate

[0063] After reacting phenol and carbon dioxide at 100 atmospheres and 125°C, sulfuric acid is added to produce p-hydroxybenzoic acid. Then use alcohol to esterify the compound, such as methanol to synthesize methyl p-hydroxybenzoate (MP).

[0064] The synthesized methyl p-hydroxybenzoate (MP) was analyzed by high performance liquid chromatography (HPLC), and the results were in figure 1 displayed in .

[0065] In addition, the synthesized methylparaben (MP) was diluted with phosphate buffered saline (PBS) and used for testing and analysis.

Embodiment 2

[0066] Embodiment 2: Hydroxyl radical scavenging ability test

[0067]To identify the ROS removal ability of methylparaben (MP), the Fenton reaction [H 2 o 2 +FeSO 4 ] produce hydroxyl radicals. The generated hydroxyl radicals were captured by nitrone spin trapping agent (DMPO), and the DMPO-OH addition products formed after capture were measured by electron spin resonance (ESR) spectrometer. ESR spectrum by reaction reagent [phosphate buffer solution (pH7.4); 4.5M DMPO10μl, 0.6mM FeSO 4 75μl, 2.8M H 2 o 2 75μl], reacted with methyl p-hydroxybenzoate and vitamin C, and then determined by ESR spectrometer (JES-FA, JEOL, Japan), the measurement results are shown in figure 2 . For this, the ESR spectrometer is analyzed with some parameters [magnetic field 340mT, power 1.0mW, frequency 9.19GHz, amplitude adjustment 0,2mT, gain 200, sweep time 2 minutes, sweep width 10mT, time constant 0.03 seconds, temperature 20°C] .

[0068] Such as figure 2 As shown, from the analys...

Embodiment 3

[0070] Example 3: Testing of Cytoprotective Activity Against Alpha (α)-Synuclein, Reactive Oxygen and Excitatory Brain Neurotransmitters

[0071] To verify whether methylparaben (MP) has cytoprotective effects against reactive oxygen species, excitatory neurotransmitters, and α-synuclein in cultured cells, a cytoprotective ability test was performed. These substances, namely, reactive oxygen species, excitatory neurotransmitters and α-synuclein have been implicated in causing widespread damage to nerve cells associated with Parkinson's and other degenerative brain diseases.

[0072] Each well of the 96-well plate contains SH-SY5Y cells (5×10 3 cells; 10% FBS supplemented with DMEM medium), cultured at 37°C for 24 hours. Then, methyl p-hydroxybenzoate (MP), 50 μM vitamin E (Vit E) or 10 μM MK-801 were added at a concentration of 1, 10 and 100 ng / ml to continue culturing for 4 hours. In addition, a culture solution to which no drug was added was prepared as a control group. A...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention relates to a pharmaceutical composition for the prevention or treatment of degenerative neurological brain disorders, and more specifically relates to a pharmaceutical composition for the prevention or treatment of degenerative neurological brain disorders such as Parkinson's disease, Alzheimer's dementia (senile dementia), stroke, Lou Gehrig's disease, Pick's disease, Creutzfeldt-Jakob disease, Huntington's disease, progressive supranuclear palsy, spinocerebellar ataxia, cerebellar atrophy, multiple sclerosis, post-traumatic stress disorder and amnesia, which composition contains a paraben compound constituting an active ingredient having effects that are useful in combating oxidation to remove active oxygen, suppressing cell-death, improving impaired movement and enhancing declining memory.

Description

technical field [0001] The present invention relates to a method for preventing or treating neurodegenerative brain disorder diseases, including Parkinson's disease, Alzheimer's disease (senile dementia), stroke, Greco's disease, Pick's disease, Creutzfeldt-Jakob disease, Huntington's disease, progressive supranuclear palsy, spinocerebellar degeneration, cerebellar atrophy, multiple sclerosis, post-traumatic stress disorder and amnesia in pharmaceutical composition. Background technique [0002] It is well known that injury-induced cell death and loss of nerve cells ("neurons") is the ultimate cause of neurodegenerative dysfunction diseases represented by Parkinson's, Alzheimer's, dementia, stroke, etc. For example, in Parkinson's disease, selective loss of dopaminergic neurons in the substantia nigra of the midbrain causes dysfunction of the basal ganglia involved in motor function, resulting in constant tremors, stiffness, slow oscillations, and postural instability (Nimi ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/235A61P25/28A61P25/00
CPCA61K31/235A61P25/00A61P25/14A61P25/16A61P25/28
Inventor 徐维宪苏希茹特·科佩勒卢秀真
Owner SEOUL NAT UNIV R&DB FOUND
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com